Tag Archives: AZBio

bioscience

Arizona bioscience industry producing ‘aha’ moments

AZBio Expo 2014 had “aha moments” at every turn. With over 250 entrepreneurs, innovators, business leaders, legislators, scientists and researchers in attendance, the energy was sizzling and the outlook endless. Here are just a few of the event highlights, appropriately, A to Z:

A – Access to Capital is the key. No money. No honey. Capital fuels innovation and commercialization. In the first panel discussion of the day – Funding Paths for Innovators – AZBio chief Joan Koerber-Walker engaged Mary Ann Guerra (BioAccel), Paul Jackson (Integrus Capital/Worthworm) and Kelly Slone (National Venture Capital Association) in a no-holds barred discussion. “The entire ecosystem has changed,” according to Slone. “After the tech bubble burst, available venture dollars have been virtually cut in half.” Guerra explains that only one in 100 will get angel funding – and then only one in 100 will get venture funding. We need to think of new ways to help our startup entrepreneurs get funding.” Jackson urges innovators to think like investors and offers one solution with his online valuation process, Worthworm.

B – Bridging the Gap with the 21st Century Cures Initiative. “No industry has to face the challenges we face to bring a product to market,” says Koerber-Walker. “We have new hope in the 21st Century Cures Initiative. Google it. Watch the videos, See what they are doing. There is exciting stuff happening and some of it is happening in Arizona.”

C — Cure Corridor. Scottsdale’s Mayor Jim Lane shares his pride and plans for the largest concentration of bioscience businesses in the U.S., the Cure Corridor, bounded on one side by the Scottsdale Airpark on the West, and the Fountain Hills Mayo facility on the East, “a major driver of our economy, with $2½ billion in direct economic impact and $3.5 billion in indirect impact.” According to Lane, “Health and wellness are a part of Scottsdale’s identity. We should never stop asking how we can find new answers alleviate pain, restore health and improve the quality of life.”

D – Discovery. Development. Delivery. Valley Fever Solutions CEO David Larwood shared his company’s formula for achieving success in development and funding – The Five R’s:

Right drug.
Right patient.
Right safety.
Right time. (How long before we can sell it?)
Right reimbursent.

E – Epigenetics and Personalized Medicine. Start-up company INanoBio founder and CEO Bharath Takupalli, explained that the genome sequencing market is expected to grow to $10 billion by 2020. With a unique capability to combine nanotechnology and biomedicine, his company is in the lead for building new solutions now. “We aim to develop a $100 ultrafast nanopore-based desktop sequencer – a point-of-care diagnostic” that will help change the face of healthcare, he explains.

F – Funding needs to be the focus for the future. According to a Flinn Foundation/Batelle report, “Arizona has many bioscience strengths and opportunities, but a substantial increase in private and public investment will be needed over the next decade to realize the [Flinn Foundation’s] Roadmap’s goals.” Last year, Arizona bioscience sector attracted $37 million in venture capital investment, up from $23 million from 2012, but that is only a fraction of the $9.8 billion invested nationally.

The goal is to increase the annual investment up to $40 million for seed capital in emerging companies and up to $125 million in venture capital.

G – Genomic advances hold high hopes for positively disruption. Explaining that healthcare premiums are growing at three times the rate of inflation and wages, Frederic Zenhausern, Ph.D., MBA, president of Whitespace Enterprise, says “The new era of precision healthcare (also called personalized healthcare) will provide more accessibility, transparency and health information to improve – dramatically – quality and lower cost over time.” His start-up company, based in Fountain Hills, develops methods for automating and miniaturizing the workflow processing of biological specimens.

H – Henry Ford.“I am looking for a lot of men who have an infinite capacity to not know what can’t be done,” said Henry Ford. So does Robert Penny, M.D., Ph.D., co-founder and CEO of the International Genomics Consortium and founder and CEO of Paradigm. “Phoenix has become the Grand Central Station for all the aggregating and analyzing cancer tissues. We have 10,000 tumors – and the information is publicly available. This will accelerate cancer discovery at a rate faster than ever,” he says. “This is a tidal wave that Arizona has led. Everyone in this room should be grabbing a surfboard and figuring out how to ride it.”

I – IPO: The nation’s top IPO of 2013 is right here in Chandler. With 380 percent growth in shareholder value, Insys Therapeutics, a commercial-stage specialty pharmaceutical company, ended the year with a market cap of $800 million. Darryl Baker, the chief financial officer, explained how the company, founded in 2002 by Dr. John Kapoor, was determined to discover better ways to deliver existing medications to patients. A sublingual fentanyl spray technology delivers treatments to opioid-tolerant cancer patients and holds real possibilities for better helping patients with acute pain, major burns and pediatric issues. In the R&D pipeline now is the development of a pharmaceutical cannabinoid, aimed at easing epilepsy, peripheral neuropathy and cocaine addiction.

J – Jobs: 107,000 bioscience jobs – good-paying and growing. Arizona has nearly 107,000 bioscience jobs, based on 2012 industry data, and the sector contributes an estimated $36 billion in revenue to the state’s economy, according to a study by the Ohio-based Battelle Technology Partnership Practice. Hospitals account for 83,000 of those jobs and $22 billion of the revenue. Arizona’s average annual wage in the bioscience sector is $62,775, 39 percent higher than the private-sector average, the report said. Not counting hospital jobs, the average wage for bioscience jobs jumps to $85,571. (2013 data).

K – Kalos Therapeutics is building a promising platform for future drug discovery. Start-up innovator Michael Kozlowski, OD, Ph.D., chief science officer of Kalos Therapeutics, explains that their focus on transforming the atrial natriuretic family of peptides engages a natural biochemical mechanism. This approach holds promise for people with pancreatic cancer because it results in a more complete response, reduced side effects and improved safety and a longer period of effectiveness.

L – Let’s leverage every resource, strength, collaboration and person we’ve got! Arizona’s bioscience industry is aiming to increase research revenue for institutions statewide by 69 percent over the next decade to $782 million and attract additional anchors for the sector.

M – Medtronic models aggressive, needs-focused growth. Keynote speaker Ron Wilson, vice president and general manager of the Medtronic Tempe campus made it clear that passion for people runs through his veins. Locating a small manufacturing facility here in 1973, the company’s facility today covers 30 acres, has 900 employees and generates $17 billion in revenues. How do they do it? We follow our founder’s vision still: We understand what the unmet needs are and we apply our knowledge for the good of people all over the world.”

N – Next Level. “Arizona has made unprecedented progress over the last decade in developing the talent, building research infrastructure, and growing its base. Taking it to the Next Level will require new collaborative partnerships, forward looking leaders, and aggressive investments from both the public and private private sectors to take our place in the top tiers globally,” shared Koerber-Walker. ”Now is our time. Let’s get it done!”

O – Orphans no more. Valley fever, considered an orphan disease, hits about 150,000 people a year – 60 percent live in central Arizona. Current treatments have major shortcomings, with about 60 percent of those treated being unresponsive. The result is 2,000 serious cases and 150 deaths a year. It affects pets in nearly equal proportion. David Larwood, CEO of Valley Fever Solutions, has some answers. His company is developing Nikkomycin Z (NikZ) as a dramatically superior potential cure for Valley Fever. To help raise awareness and prevention, the Arizona Board of Regents created Valley Fever Corridor project, a public health program led by University of Arizona College of Medicine’s John Galgiani, MD, who is also the chief medical officer for Valley Solutions.

P – Policymakers are on board. Gov. Jan Brewer’s time is coming to a close and it’s time to decide which candidate can bring their best to bioscience. Recognizing that the Arizona bioscience sector is growing at four times the rate of the national average, candidates Christine Jones, Doug Ducey, Fred Duval, Ken Bennett and Scott Smith shared their ideas on how to ramp up funding and revenues in 90-second videos. Koerber-Walker says, “The most important thing we can do this summer is vote in the primaries.”

Q – Cues: Here are a few Q’s for success. Some lessons learned, courtesy of Robert Penny:

Make sure you have:

Complementary skills and expertise
Trust
Interpersonal chemistry (It’s better to navigate bumps in the road with people you trust than people you don’t!)

Pick the right projects:

Big enough to be worthy of your efforts
Complex enough to need partnerships
Audacious enough to move the field

R – Remembering Polio: Can Looking Back Catapult Us Forward? How did we cure the world of polio? What did it take to conquer the most feared disease of the 20th Century? What threatens our world today and how can we continue to keep people healthy with the right vaccines, for the right person at the right time? Gaspar Laca, state government affairs director at GlaxoSmithKime, engaged David Larwood, CEO and president of Valley Fever Solutions (and a person who has been directly affected by polio) and Rep. Debbie McCune Davis, executive director of The Arizona Partnership for Immunization, in a rousing discussion of what’s happening in Arizona today, the mounting threats of the ”vaccine exemptors,” and what we need to do now. (See Vaccines.)

S – Shoes. Did you see those shoes? “Give a girl the right shoes and she can conquer the world!” Enough said.

T – Tucson’s Critical Path Institute creates new tools. A jewel in the bioscience crown – and located right here in Arizona! The Critical Path Institute (C-Path) is a breakthrough organization, creating a new movement: “consensus science.” Keynoter Martha Brumfield. Ph.D, president and CEO, shared what can be achieved when people come together with the belief that a “rising tide floats all boats.” Working to improve the unacceptable 95 percent failure rate in the testing of new drug therapies, C-Path is improving medical product development efficiencies by identifying pathways that integrate new scientific advances into the regulatory review process. Check out their Alzheimer’s clinical trial simulation tool.

U – United we stand. Mayors Jim Lane (City of Scottsdale) and John Lewis (Town of Gilbert) will join Koerber-Walker and an Arizona bioscience-business contingent next week at the 2014 BIO International Convention in San Diego (June 23-26), the world’s largest biotechnology gathering. They will surely scoop up new ideas, new connections – and with any luck, new investment!

V – Vaccines: Get ‘em! Talk about ‘em. Challenge the myths. Explain the realities. Polio. Measles. And whooping cough today. Without proper vaccinations, whooping cough (pertussis) could be the polio of our time. “As science-minded people, the best thing you can do is activate conversations about the importance of vaccinations. Here’s some help: Why immunize?

W – White Hat event brings in national investors. (Apply by July 15th.) “AZBio’s White Hat Investor’s Conference is the first ever life science specific investor conference to be held in Arizona,” says Koerber-Walker. “Kelly Slone [of the National Venture Capital Association] has been an amazing partner to bring this together along with the state bioscience association leaders from across the Rocky Mountain Southwest Region. Investors and investment firms from across the country will be here, so get involved. Even if you feel like you are not ready yet, take the leap and apply to present. “

X – “X” marks the spot for our next big gathering. Wear your White Hat! The West was won by innovators, investors, and prospectors who understood the value of discovery and accepted the challenge of investing in new frontiers. Meet a new generation of biotech and healthcare pioneers at White Hat Investors 2014, the first annual biotech and healthcare investor conference that showcases the best of the Rocky Mountain & Southwest Region.

Bioindustry Associations from across the Rocky Mountain and Southwest Region are coming together to present an opportunity for Angels, Venture Capitalists and Strategic Investors to connect with the best biotech and healthcare investment opportunities from across the Rocky Mountain & Southwest states at White Hat Investors 2014 in Phoenix, Arizona on September 17 & 18, 2014.

Presenting Companies will be selected from the region’s emerging innovator leaders in the fields of:

Diagnostics
Therapeutics
Medical Devices
Health IT

Y – Young Talent is being cultivated. We got it! With nearly 50 abstracts accepted and student presenters presenting at the Expo, Koerber-Walker got it right when she said, “These young people are going to be working on things that we can’t even begin to imagine!” Arizona’s tremendous mentoring people and organizations are sharing knowledge, support and inspiration. For example University of Arizona student Keeley Brown is destined to help the world crack the code on genetically modified foods and farming. (Her presentation was the “Epigenetic Effects of Transgenic Manipulation in Glycine Max (Soybeans).

Zzzzzzzzz – No one fell asleep at this conference! Catherine Leyen, founder and CEO of start-up RadiUp, says she comes to AZBio to stay abreast of the action, connect with like-minded people and soak up inspiration. Her verdict of AZBIO Expo 2014? Mission accomplished!

bioscience

Bioindustry honors Innovators at AZBio Awards

The Arizona Bioindustry Association (AZBio) today announced that more than 350 leaders from across the State of Arizona will be gathering at the Phoenix Convention Center on October 10, 2013 to celebrate AZBio’s 10thanniversary as Arizona’s statewide bioindustry association and to recognize the leaders, innovators and companies that are making Arizona one of the fastest growing bioscience states in the nation.

“Over the last decade, Arizona’s bioindustry has delivered an aggregate job growth of 45% (2002-2011) and an increase in the number of healthcare and bioscience firms by 31%,” shared AZBio President and CEO Joan Koerber-Walker. “This is the result of executives, innovators, researchers, educators, and elected leaders working together to embrace possibilities and collaboratively create a fast growing industry that is creating high wage jobs and addressing some of our greatest challenges: improving health and creating new industries that leverage our natural resources and our steadily increasing collection of internationally recognized talent.”

In addition to honoring the hundreds of organizations that have worked together over the last 10 years to create and drive life science innovation in Arizona, the AZBio Awards recognize specific thought leaders and industry leaders for their contributions. Attendees will have the opportunity to learn about and gain insights from:

  • Thomas M. Grogan, M.D., Founder of Ventana and SVP Medical Affairs at Ventana Medical Systems, Inc., a member of the Roche Group and recipient of the AZBio Pioneer Award for Lifetime Achievement honoree.
  • Linda Hunt, President and CEO of Dignity Health Arizona, the 2013 Jon W. McGarity Arizona Bioscience Leader of the Year.
  • Amanda Grimes of the Mesa Biotechnology Academy in the Mesa Public Schools, recipient of the Michael A. Cusanovich Arizona Bioscience Educator of the Year Award for inspiring students to explore careers in the biosciences.
  • Orphan drug pioneer Leslie Boyer, M.D., founding director of the VIPER Institute at The University of Arizona. With her team of international collaborators developed the FDA approved anti-venom for the scorpion’s sting.
  • John W. Lewis, Mayor of the Town of Gilbert, Arizona recipient of the AZBio Public Service Award for his leadership in attracting and supporting the development of world class research, manufacturing and clinical services in Gilbert.
  • The team from Arizona Bioscience Company of the Year – W.L. Gore & Associates, Inc., Arizona’s largest life science employer. The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 35 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide Gore has been granted more than 2,000 patents worldwide ranging from polymer processing to medical devices.
  • Dr. Robert Bowser, AZBio Fast Lane Award winner for pioneering new diagnostics for ALS and traumatic brain injury at Iron Horse Diagnostics, Inc.
  • Dr. Garrett Smith, co-founder of Nasseo, Inc., the Fast Lane Award winning company that has developed the FDA approved TiArray™ Dental Implant.
  • Jeff Martin, CEO of Fast Lane Award winner Yulex Corporation and the team that delivers Yulex’s Guayule BioRubber Emulsions and BioRubber Solids that have medical, consumer, and industrial applications to grow an increasingly diverse market community with ultra-pure, high-performance products.
  • And executives from Algae Biosciences, Ventana, Pfizer, Genentech, EY, Northern Arizona University/TGen North, Regenesis Biomedical, Ulthera, VWR, and NACET.

The 8th Annual AZBio Awards will be held Thursday, October 10, 2013 at the Phoenix Convention Center. In addition to the Gala Awards Luncheon from 11:30 a.m. to 2:00 p.m., the VWR Company Showcase and Student Discovery Showcase sponsored by NAU will highlight the work of Arizona’s current and future life science leaders from 10 a.m. – 11:30 a.m. and again from 2:00 p.m. – 3:00 p.m. so that attendees can see the work being done across the industry and interact with the leaders and future leaders who are driving bioindustry innovation. The event is open to the public and tickets are available for purchase at AZBioAwards.com.

“Almost 100,000 Arizonans are embracing possibilities every day across Arizona’s healthcare and life science sector. Through their efforts, we are making life better here at home and around the world by discovering, developing, and delivering life science innovations,” added Koerber-Walker. “AZBio is honored to have the opportunity to work with them and to bring so many of our leaders together in one place on one day so our community can meet them and learn about them too.”

woman

Women Investing In Women announces summit plans

Women Investing In Women announced that their Inaugural Women Investing in Women Summit, at the Arizona Biltmore on 12/12/12, will bring together over 150 professional women from across the Valley to discuss important issues and opportunities, build new relationships and celebrate our accomplishments in 2012.

Anu Bhardwaj, WIIW’s founder stated, “I appreciate all the support from our valued sponsors, luminary speakers, and community partners that are helping bring the Women Investing In Women Summit to Arizona — by supporting our mission of creating a cohesive platform for women in Financial Literacy, through education, entrepreneurship and providing access to capital markets”.

Kathy Lynn-Cullotta, co-president of 85 Broads Phoenix, said “We are very excited to help support the WIIW mission and be a partner in bringing this wonderful event to the women business owners in Arizona.”

WIIW Summit topics on 12-12-12 will include Impact Investing with guest panel Natalia Oberti Noguera, founder of Pipeline Fellowship; Michelle Mace, ASU Women & Philanthropy; Jackie Sturm, Intel’s global strategic initiatives.

Continuing the WIIW Summit with a luncheon conversation about Board Diversity and women’s participating in the  2020 Women on Boards Campaign which is a national campaign to increase the percentage of women directors on U.S. public company boards to 20 percent or greater by 2020.  Our Arizona Summit keynote speaker Dr. Mary Walshok, founder of Global CONNECT / Dean of the UCSD Extension School and the Summit discussion will be led by Shelly Esque, Intel’s Corporate Affairs Group and include Joanne Flynn, Managing Director, Phoenix Group International.

The One Day summit Educational Track’s will include a variety of speakers and topics including Branding Your Brilliance, Women’s Access to Capital, Women’s Angel Investors in Arizona, Women Entrepreneurs Building New Companies Faster, The Lean Launch pad Way, and Pitching like a Rock Star with Candace Klein, founder of SoMoLend.

WIIW 2012 Summit Sponsors and Partners include Intel, Venture Catalyst Private Equity Partners, 85 Broads Phoenix, Premier Media Service, Nautilus Group / New York Life, 2020 Women on Boards, NetGains America, Quarles & Brady, The Valley Girl Show, Arizona State University, NAWBO, AZBIO, MBAWI, Global CONNECT, Women & Philanthropy, SEEDSPOT, Thunderbird Online.

Sign up today to attend 12-12-12 Women Investing In Women at Arizona Biltmore a Full Day Program is only $175 Includes Breakfast, Lunch, Dinner all the Educational Tracks and Summit Access.

Women Investing in Women is a branded platform of high impact educational programs and public-private partnerships emphasizing financial literacy and entrepreneurship by women for women, globally.  These programs will be held internationally to provide continuing education to address the need for high quality online content and interactive event formats that foster broader access to capital for women and the growth of women-led businesses.

133885164

TGen’s Keim named AZBio’s 2012 Bioscience Researcher of the Year

TGDr. Paul Keim, Director of the Pathogen Genomics Division of the Translational Genomics Research Institute (TGen) and the Cowden Endowed Chair of Microbiology at Northern Arizona University (NAU), will receive the 2012 Bioscience Researcher of the Year award from the Arizona BioIndustry Association (AZBio).

“Dr. Keim was nominated by members of the Arizona Bioscience Community and selected by an independent, statewide panel of leaders for this recognition of his research and innovation in the field of pathogen genomics and microbiology,” said AZBio President and CEO Joan Koerber-Walker.

His award will be presented at the 7th annual AZBio Awards on Oct. 23 at the Phoenix Convention Center. An industry showcase and student discovery session are scheduled from 3-5:30 p.m., and the awards gala is from 6-9 p.m.

“AZBio’s recognition of Dr. Keim is extraordinarily well deserved,” said TGen President and Scientific Director Dr. Jeffrey Trent. “Paul’s unique achievements in interpreting the microbial genomes of pathogens — both those that naturally cause disease, but also those made into weapons by terrorists — are of profound importance.  His research, coupled to his dedications to his students and to the cause of public health globally, place him in the upper echelon of premier scientists, and puts Arizona on the map in this critical growing area of research.”

Dr. Keim is a world-renowned expert in anthrax and other infectious diseases. At TGen and NAU he directs investigations into how to bolster the nation’s biodefense, and to prevent outbreaks — even pandemics — of such contagions as flu, cholera, E. coli, salmonella, and even the plague.

“Our science has been completely transformed by the rapid advancements of technology. Now, TGen’s job is to rapidly advance our science to make great impacts on human health. We have that ability, therefore, we feel that we have that responsibility,” said Dr. Keim, a Professor at TGen and Regents Professor of Microbiology at NAU.

Dr. Keim also is Director of NAU’s Microbial Genetics & Genomics Center, a program that works with numerous government agencies to help thwart bioterrorism and the spread of pathogen-caused diseases.

Since 2004, he has been a member of the federal government’s National Science Advisory Board for Biosecurity (NSABB). He helped draft national guidelines for blunting bioterrorism while elevating ethical standards and improving the quality of scientific research. Dr. Keim’s work at the NSABB includes recently serving two years as the acting Chair.

While TGen this year celebrates a decade of progress, TGen’s Pathogen Genomics Division, also known as TGen North in Flagstaff, is celebrating five years of protecting human health though genomic investigations of some of humankind’s most deadly microbes.

“Paul Keim’s work ranges broadly — from plague in prairie dogs, to cholera in Haiti,” said NAU Provost Laura Huenneke. “Here at NAU, literally hundreds of students, both undergraduate and graduate, have participated in that research and launched from there into successful careers. His research group has also grown into the strong partnership between the university and TGen North — a huge economic development dividend for Flagstaff.’’